MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.
Standard
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. / Holtkamp, Nikola; Atallah, Isis; Okuducu, Ali-Fuat; Mucha, Jana; Hartmann, Christian; Mautner, Viktor Felix; Friedrich, Reinhard; Mawrin, Christian; von Deimling, Andreas.
In: NEOPLASIA, Vol. 9, No. 8, 8, 2007, p. 671-677.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.
AU - Holtkamp, Nikola
AU - Atallah, Isis
AU - Okuducu, Ali-Fuat
AU - Mucha, Jana
AU - Hartmann, Christian
AU - Mautner, Viktor Felix
AU - Friedrich, Reinhard
AU - Mawrin, Christian
AU - von Deimling, Andreas
PY - 2007
Y1 - 2007
N2 - Malignant peripheral nerve sheath tumors (MPNST) are sarcomas with poor prognosis and limited treatment options. Factors contributing to tumor progression are largely unknown. We therefore examined MPNST from 22 neurofibromatosis type 1 (NF1) patients, 14 non-NF1 patients, and 14 neurofibroma patients for matrix metalloproteinase 13 (MMP-13) expression. Because wild-type and mutant p53 were shown to differentially regulate MMP-13 expression, TP53 status and protein levels were also determined. MMP-13 expression was detected in 58% of MPNST and was significantly associated with recurrent MPNST (P = .019). p53 was observed in 78% of MPNST and was found to be strongly associated with MMP-13 expression (P = .005). In contrast, 14 neurofibromas lacked MMP-13 and p53 expressions. TP53 mutations were found in only 11% of MPNST and were associated with high tumor grades (P = .029). No significant association between mutant TP53 and MMP-13 was observed, indicating that other factors drive MMP-13 expression in MPNST. The presence of metastasis was linked to p53Pro(72) polymorphism (P = .041) and shorter survival. In summary, our data suggest that MMP-13 expression in nerve sheath tumors is coupled with malignant progression. Therefore, MMP-13 may serve as a marker for progression and as a therapeutic target.
AB - Malignant peripheral nerve sheath tumors (MPNST) are sarcomas with poor prognosis and limited treatment options. Factors contributing to tumor progression are largely unknown. We therefore examined MPNST from 22 neurofibromatosis type 1 (NF1) patients, 14 non-NF1 patients, and 14 neurofibroma patients for matrix metalloproteinase 13 (MMP-13) expression. Because wild-type and mutant p53 were shown to differentially regulate MMP-13 expression, TP53 status and protein levels were also determined. MMP-13 expression was detected in 58% of MPNST and was significantly associated with recurrent MPNST (P = .019). p53 was observed in 78% of MPNST and was found to be strongly associated with MMP-13 expression (P = .005). In contrast, 14 neurofibromas lacked MMP-13 and p53 expressions. TP53 mutations were found in only 11% of MPNST and were associated with high tumor grades (P = .029). No significant association between mutant TP53 and MMP-13 was observed, indicating that other factors drive MMP-13 expression in MPNST. The presence of metastasis was linked to p53Pro(72) polymorphism (P = .041) and shorter survival. In summary, our data suggest that MMP-13 expression in nerve sheath tumors is coupled with malignant progression. Therefore, MMP-13 may serve as a marker for progression and as a therapeutic target.
U2 - 10.1593/neo.07304
DO - 10.1593/neo.07304
M3 - SCORING: Zeitschriftenaufsatz
VL - 9
SP - 671
EP - 677
JO - NEOPLASIA
JF - NEOPLASIA
SN - 1476-5586
IS - 8
M1 - 8
ER -